H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25 Click here for complete report and disclosures
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019 Stonegate Partners Updated Report – January 2019
Drug Development and Delivery Published Article: DNA THERAPEUTICS – DNAbilize-ING Antisense Published Article
Published Article: Evolution of Antisense Oligonucleotides in Oncology Published Article Evolution of Antisense in Oncology
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01 BP1001 Review Article See Also: BP1001 animal studies BP1001 leukemia cell line studies
